SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults
Use of sodium-glucose cotransporter-2 (SGLT2) inhibitors does not appear to raise the risk for fractures in older adults, new research […]
The AMPLITUDE-O phase 3 trial showed that investigational drug efpeglenatide (Sanofi/Hanmi Pharmaceutical) — an exendin-based glucagon-like peptide-1 (GLP-1) receptor agonist […] Cardiovascular disease was the leading cause of death among the over 16,000 patients with type 2 diabetes (T2DM) who were […] Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The US Centers for Disease Control […] JERUSALEM (Reuters) – Israeli medical software company DreaMed Diabetes said on Monday it was partnering with Yale New Haven Health […]diabetes mellitus type 2
AMPLITUDE-O: Efpeglenatide Benefits in High-Risk Diabetes
CVD Remains Leading Cause of Death in Type 2 Diabetes
CDC Adds New Medical Conditions to COVID-19 High-Risk List
Israel’s DreaMed, Yale Team Up on AI Diabetes Monitoring